Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SONN | US
-0.20
-3.38%
Healthcare
Biotechnology
30/06/2024
21/10/2024
5.71
6.07
6.26
5.60
Sonnet BioTherapeutics Holdings Inc. a clinical stage oncology-focused biotechnology company develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010 a fully human version of interleukin 12 for the treatment non-small cell lung cancer and head and neck cancer and is under phase 1 trial. The company is also developing SON-080 a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210 a bispecific compound developed for solid tumor indications including colorectal cancer. It has a license agreement with New Life Therapeutics Pte LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton New Jersey.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
119.6%1 month
141.6%3 months
107.7%6 months
102.7%-
-
1.52
0.06
0.03
-0.21
10.19
-
-12.26M
3.71M
3.71M
-
-21.97K
-
-50.00
-264.57
0.99
2.02
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.14
Range1M
6.28
Range3M
6.34
Rel. volume
0.53
Price X volume
123.97K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fresh America Corp | FRES | Biotechnology | 1.66 | 4.07M | -15.74% | n/a | 0.22% |
Lipella Pharmaceuticals Inc. Common Stock | LIPO | Biotechnology | 0.4896 | 3.97M | -0.99% | n/a | 5.50% |
Windtree Therapeutics Inc | WINT | Biotechnology | 1.07 | 3.94M | 17.16% | n/a | 36.99% |
Genprex Inc | GNPX | Biotechnology | 1.51 | 3.91M | 265.62% | n/a | 0.00% |
InMed Pharmaceuticals Inc | INM | Biotechnology | 0.29 | 3.87M | 21.04% | n/a | 7.00% |
Neurotrope Inc | NTRP | Biotechnology | 2.4 | 3.80M | 0.00% | n/a | 0.00% |
Gritstone Oncology Inc - Ordinary Shares | GRTS | Biotechnology | 0.0322 | 3.80M | -31.78% | n/a | 461.91% |
Oragenics Inc | OGEN | Biotechnology | 0.345 | 3.63M | 5.83% | n/a | 0.00% |
Virpax Pharmaceuticals Inc | VRPX | Biotechnology | 0.7216 | 3.53M | 6.15% | n/a | 0.00% |
Biodexa Pharmaceticals | BDRX | Biotechnology | 5.98 | 3.47M | 4.91% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.21 | 0.53 | Cheaper |
Ent. to Revenue | 10.19 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 1.52 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 107.67 | 72.80 | Riskier |
Debt to Equity | 0.06 | -1.23 | Expensive |
Debt to Assets | 0.03 | 0.25 | Cheaper |
Market Cap | 3.71M | 3.66B | Emerging |